Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Express Scripts
Harvard Business School

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017962

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 017962 describes PARLODEL, which is a drug marketed by Us Pharms Holdings I and is included in one NDA. It is available from two suppliers. Additional details are available on the PARLODEL profile page.

The generic ingredient in PARLODEL is bromocriptine mesylate. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
Summary for 017962
Tradename:PARLODEL
Applicant:Us Pharms Holdings I
Ingredient:bromocriptine mesylate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 017962
Medical Subject Heading (MeSH) Categories for 017962
Suppliers and Packaging for NDA: 017962
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962 NDA Validus Pharmaceuticals LLC 30698-201 30698-201-01 100 CAPSULE, GELATIN COATED in 1 BOTTLE (30698-201-01)
PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962 NDA Validus Pharmaceuticals LLC 30698-201 30698-201-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (30698-201-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Mar 1, 1982TE:ABRLD:Yes

Expired US Patents for NDA 017962

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982   Start Trial   Start Trial
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Harvard Business School
Mallinckrodt
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.